TY - ECHAP
KW - ancestry
KW - Population descriptors
KW - Preclinical nonanimal studies
AU - Erika Moore
AU - Alison Veintimilla
AU - Nana Owusu-Boaitey
AU - Connie J. Mulligan
AU - Catharine E. Krebs
AU - Gail A. Van Norman
AB - Social and genetic ancestry remain important determinants of human health. Preclinical research and wider society use population descriptors to characterize ancestry. The successful application of these descriptors requires clear, meaningful definitions and awareness of how those performing and evaluating research may use these terms in a biased manner. Ancestry descriptors can be employed together with effective human-based preclinical modeling methods. This encompasses ex vivo studies using cells and other components isolated from patients, in vitro analyses conducted in laboratory settings, and computer-based in silico studies. These preclinical modeling methods improve understanding of the role of ancestry in disease mechanisms, therapeutics, and diagnosis, providing important advantages over animal-based methods. Maximizing the strengths of preclinical modeling and mitigating its limitations may require collaboration between stakeholders such as researchers, research participants, and advocacy groups. Collaboration facilitates preclinical modeling that produces scientifically rigorous results on ancestry in a manner respectful of vulnerable communities.
BT - Moving Toward Nonanimal Approaches in Medical Research and Testing
DA - 2027-01-01
N2 - Social and genetic ancestry remain important determinants of human health. Preclinical research and wider society use population descriptors to characterize ancestry. The successful application of these descriptors requires clear, meaningful definitions and awareness of how those performing and evaluating research may use these terms in a biased manner. Ancestry descriptors can be employed together with effective human-based preclinical modeling methods. This encompasses ex vivo studies using cells and other components isolated from patients, in vitro analyses conducted in laboratory settings, and computer-based in silico studies. These preclinical modeling methods improve understanding of the role of ancestry in disease mechanisms, therapeutics, and diagnosis, providing important advantages over animal-based methods. Maximizing the strengths of preclinical modeling and mitigating its limitations may require collaboration between stakeholders such as researchers, research participants, and advocacy groups. Collaboration facilitates preclinical modeling that produces scientifically rigorous results on ancestry in a manner respectful of vulnerable communities.
PB - Academic Press
PY - 2027
SN - 978-0-443-26514-3
SP - 177
EP - 188
T2 - Moving Toward Nonanimal Approaches in Medical Research and Testing
TI - Chapter 11 - Emphasizing ancestry in human-based biomedical research
UR - https://www.sciencedirect.com/science/article/pii/B9780443265143000047
Y2 - 2026-10-05
ER -